These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 22960405

  • 1. Receptor-mediated inhibition of small bowel migrating complex by GLP-1 analog ROSE-010 delivered via pulmonary and systemic routes in the conscious rat.
    Hellström PM, Smithson A, Stowell G, Greene S, Kenny E, Damico C, Leone-Bay A, Baughman R, Grant M, Richardson P.
    Regul Pept; 2012 Nov 10; 179(1-3):71-6. PubMed ID: 22960405
    [Abstract] [Full Text] [Related]

  • 2. Inhibitory effect of glucagon-like peptide-1 on small bowel motility. Fasting but not fed motility inhibited via nitric oxide independently of insulin and somatostatin.
    Tolessa T, Gutniak M, Holst JJ, Efendic S, Hellström PM.
    J Clin Invest; 1998 Aug 15; 102(4):764-74. PubMed ID: 9710445
    [Abstract] [Full Text] [Related]

  • 3. GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome.
    Hellström PM, Näslund E, Edholm T, Schmidt PT, Kristensen J, Theodorsson E, Holst JJ, Efendic S.
    Neurogastroenterol Motil; 2008 Jun 15; 20(6):649-59. PubMed ID: 18298441
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Receptor-mediated activation of gastric vagal afferents by glucagon-like peptide-1 in the rat.
    Bucinskaite V, Tolessa T, Pedersen J, Rydqvist B, Zerihun L, Holst JJ, Hellström PM.
    Neurogastroenterol Motil; 2009 Sep 15; 21(9):978-e78. PubMed ID: 19453518
    [Abstract] [Full Text] [Related]

  • 9. Glucagon-like peptide-1 analogue LY315902: effect on intestinal motility and release of insulin and somatostatin.
    Näslund E, Skogar S, Efendic S, Hellström PM.
    Regul Pept; 2002 Jun 15; 106(1-3):89-95. PubMed ID: 12047915
    [Abstract] [Full Text] [Related]

  • 10. GLP-1: broadening the incretin concept to involve gut motility.
    Hellström PM.
    Regul Pept; 2009 Aug 07; 156(1-3):9-12. PubMed ID: 19362109
    [Abstract] [Full Text] [Related]

  • 11. Role of glucagon-like peptide-1 in the pathogenesis of experimental irritable bowel syndrome rat models.
    Chen Y, Li Z, Yang Y, Lin L, Zhang H.
    Int J Mol Med; 2013 Mar 07; 31(3):607-13. PubMed ID: 23338623
    [Abstract] [Full Text] [Related]

  • 12. Neuromedin-N inhibits migrating myoelectric complex and induces irregular spiking in the small intestine of rats; comparison with neurotensin.
    Schultz I, Wallin B, Mogard MH, Hellström PM.
    Regul Pept; 1991 Sep 03; 35(3):197-205. PubMed ID: 1758975
    [Abstract] [Full Text] [Related]

  • 13. Glucagon-Like Peptide-1 Inhibits Prandial Gastrointestinal Motility Through Myenteric Neuronal Mechanisms in Humans.
    Halim MA, Degerblad M, Sundbom M, Karlbom U, Holst JJ, Webb DL, Hellström PM.
    J Clin Endocrinol Metab; 2018 Feb 01; 103(2):575-585. PubMed ID: 29177486
    [Abstract] [Full Text] [Related]

  • 14. Nitrergic inhibition of migrating myoelectric complex in the rat is mediated by vasoactive intestinal peptide.
    Hellström PM, Ljung T.
    Neurogastroenterol Motil; 1996 Dec 01; 8(4):299-306. PubMed ID: 8959734
    [Abstract] [Full Text] [Related]

  • 15. Physiological regulation and NO-dependent inhibition of migrating myoelectric complex in the rat small bowel by OXA.
    Ehrström M, Näslund E, Ma J, Kirchgessner AL, Hellström PM.
    Am J Physiol Gastrointest Liver Physiol; 2003 Oct 01; 285(4):G688-95. PubMed ID: 12816759
    [Abstract] [Full Text] [Related]

  • 16. The common hepatic branch of the vagus is not required to mediate the glycemic and food intake suppressive effects of glucagon-like-peptide-1.
    Hayes MR, Kanoski SE, De Jonghe BC, Leichner TM, Alhadeff AL, Fortin SM, Arnold M, Langhans W, Grill HJ.
    Am J Physiol Regul Integr Comp Physiol; 2011 Nov 01; 301(5):R1479-85. PubMed ID: 21849636
    [Abstract] [Full Text] [Related]

  • 17. Regional differences in the effects of various doses of cerulein upon the small-intestinal migrating motor complex in fasted and non-fasted sheep.
    Romański KW.
    J Anim Physiol Anim Nutr (Berl); 2007 Feb 01; 91(1-2):29-39. PubMed ID: 17217388
    [Abstract] [Full Text] [Related]

  • 18. Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor.
    Ban K, Kim KH, Cho CK, Sauvé M, Diamandis EP, Backx PH, Drucker DJ, Husain M.
    Endocrinology; 2010 Apr 01; 151(4):1520-31. PubMed ID: 20172966
    [Abstract] [Full Text] [Related]

  • 19. Circulating glucagon-like peptide-1 (GLP-1) inhibits eating in male rats by acting in the hindbrain and without inducing avoidance.
    Punjabi M, Arnold M, Rüttimann E, Graber M, Geary N, Pacheco-López G, Langhans W.
    Endocrinology; 2014 May 01; 155(5):1690-9. PubMed ID: 24601880
    [Abstract] [Full Text] [Related]

  • 20. PYY and GLP-1 contribute to feedback inhibition from the canine ileum and colon.
    Wen J, Phillips SF, Sarr MG, Kost LJ, Holst JJ.
    Am J Physiol; 1995 Dec 01; 269(6 Pt 1):G945-52. PubMed ID: 8572226
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.